Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia

Tervonen, HE; Chen, TYT; Lin, E; Boyle, FM; Moylan, EJ; Della-Fiorentina, SA; Beith, J; Johnston, A; Currow, DC

Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia

Tervonen, HE Chen, TYT Lin, E Boyle, FM Moylan, EJ Della-Fiorentina, SA Beith, J Johnston, A Currow, DC

Permalink

Publication Type:: Journal Article
Citation:: European Journal of Cancer Care, 2019, 28 (5)
Issue Date:: 2019-09-01

Closed Access

	Filename	Description	Size
	Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia.pdf	Published Version	474.33 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Tervonen, HE	en_US
dc.contributor.author	Chen, TYT	en_US
dc.contributor.author	Lin, E	en_US
dc.contributor.author	Boyle, FM	en_US
dc.contributor.author	Moylan, EJ	en_US
dc.contributor.author	Della-Fiorentina, SA	en_US
dc.contributor.author	Beith, J	en_US
dc.contributor.author	Johnston, A	en_US
dc.contributor.author	Currow, DC https://orcid.org/0000-0003-1988-1250	en_US
dc.date.available	2019-05-27	en_US
dc.date.issued	2019-09-01	en_US
dc.identifier.citation	European Journal of Cancer Care, 2019, 28 (5)	en_US
dc.identifier.issn	0961-5423	en_US
dc.identifier.uri	http://hdl.handle.net/10453/139196
dc.description.abstract	© 2019 John Wiley & Sons Ltd Objective: To examine risk of emergency hospital admission and survival following adjuvant chemotherapy for early breast cancer. Methods: Linked data from New South Wales population-based and clinical cancer registries (2008–2012), hospital admissions, official death records and pharmaceutical benefit claims. Women aged ≥18 years receiving adjuvant chemotherapy for early-stage operable breast cancer in NSW public hospitals were included. Odds ratios (OR) for emergency hospitalisation within 6 months following chemotherapy initiation were estimated using logistic regression and survival using Kaplan–Meier and Cox proportional hazards methods. Results: A total of 3,950 women were included and 30.6% were hospitalised. The most common principal diagnosis at admission was neutropenia (30.8%). Women receiving docetaxel/carboplatin/trastuzumab (TCH) and docetaxel/cyclophosphamide (TC) were the most frequently hospitalised. After adjustment for demographic and clinical factors, the increased risk of hospitalisation for TCH and TC remained compared with doxorubicin/cyclophosphamide 3-weekly (OR 1.71, 95% confidence interval [CI] 1.24–2.37 and OR 1.47, 95% CI 1.17–1.85 respectively). Five-year overall survival was similar for women who were (92.2%, 95% CI 90.7–93.8) and were not hospitalised (93.1%, 95% CI 92.1–94.1). Conclusion: Emergency hospitalisations following chemotherapy for early breast cancer were relatively common, especially following docetaxel-containing protocols. Further examination of reasons for admission is needed to inform actions to improve patient safety.	en_US
dc.relation.ispartof	European Journal of Cancer Care	en_US
dc.relation.isbasedon	10.1111/ecc.13125	en_US
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.classification	Oncology & Carcinogenesis	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Breast Neoplasms	en_US
dc.subject.mesh	Neutropenia	en_US
dc.subject.mesh	Emergencies	en_US
dc.subject.mesh	Fever	en_US
dc.subject.mesh	Cyclophosphamide	en_US
dc.subject.mesh	Carboplatin	en_US
dc.subject.mesh	Antineoplastic Combined Chemotherapy Protocols	en_US
dc.subject.mesh	Chemotherapy, Adjuvant	en_US
dc.subject.mesh	Hospitalization	en_US
dc.subject.mesh	Mastectomy	en_US
dc.subject.mesh	Mastectomy, Segmental	en_US
dc.subject.mesh	Survival Rate	en_US
dc.subject.mesh	Logistic Models	en_US
dc.subject.mesh	Proportional Hazards Models	en_US
dc.subject.mesh	Odds Ratio	en_US
dc.subject.mesh	Risk Factors	en_US
dc.subject.mesh	Retrospective Studies	en_US
dc.subject.mesh	Cohort Studies	en_US
dc.subject.mesh	Adult	en_US
dc.subject.mesh	Aged	en_US
dc.subject.mesh	Middle Aged	en_US
dc.subject.mesh	New South Wales	en_US
dc.subject.mesh	Female	en_US
dc.subject.mesh	Kaplan-Meier Estimate	en_US
dc.subject.mesh	Chemotherapy-Induced Febrile Neutropenia	en_US
dc.subject.mesh	Trastuzumab	en_US
dc.subject.mesh	Docetaxel	en_US
dc.subject.mesh	Infections	en_US
dc.title	Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia	en_US
dc.type	Journal Article
utslib.citation.volume	5	en_US
utslib.citation.volume	28	en_US
utslib.for	1110 Nursing	en_US
utslib.for	1112 Oncology and Carcinogenesis	en_US
utslib.for	1117 Public Health and Health Services	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	closed_access	*
pubs.issue	5	en_US
pubs.publication-status	Published	en_US
pubs.volume	28	en_US

Abstract:

© 2019 John Wiley & Sons Ltd Objective: To examine risk of emergency hospital admission and survival following adjuvant chemotherapy for early breast cancer. Methods: Linked data from New South Wales population-based and clinical cancer registries (2008–2012), hospital admissions, official death records and pharmaceutical benefit claims. Women aged ≥18 years receiving adjuvant chemotherapy for early-stage operable breast cancer in NSW public hospitals were included. Odds ratios (OR) for emergency hospitalisation within 6 months following chemotherapy initiation were estimated using logistic regression and survival using Kaplan–Meier and Cox proportional hazards methods. Results: A total of 3,950 women were included and 30.6% were hospitalised. The most common principal diagnosis at admission was neutropenia (30.8%). Women receiving docetaxel/carboplatin/trastuzumab (TCH) and docetaxel/cyclophosphamide (TC) were the most frequently hospitalised. After adjustment for demographic and clinical factors, the increased risk of hospitalisation for TCH and TC remained compared with doxorubicin/cyclophosphamide 3-weekly (OR 1.71, 95% confidence interval [CI] 1.24–2.37 and OR 1.47, 95% CI 1.17–1.85 respectively). Five-year overall survival was similar for women who were (92.2%, 95% CI 90.7–93.8) and were not hospitalised (93.1%, 95% CI 92.1–94.1). Conclusion: Emergency hospitalisations following chemotherapy for early breast cancer were relatively common, especially following docetaxel-containing protocols. Further examination of reasons for admission is needed to inform actions to improve patient safety.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/139196